Media coverage about Natus Medical (NASDAQ:BABY) has trended somewhat positive on Wednesday, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Natus Medical earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 46.7072242174841 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Several analysts recently issued reports on BABY shares. Zacks Investment Research upgraded Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research report on Tuesday, October 24th. BidaskClub cut Natus Medical from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. William Blair cut Natus Medical from an “outperform” rating to a “market perform” rating in a research report on Monday, January 8th. Finally, Benchmark reiterated a “buy” rating and set a $49.00 target price (down previously from $55.00) on shares of Natus Medical in a research report on Tuesday, January 16th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $47.00.

Shares of Natus Medical (NASDAQ BABY) opened at $31.45 on Wednesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.36 and a current ratio of 4.21. Natus Medical has a 1 year low of $28.05 and a 1 year high of $43.60. The stock has a market capitalization of $995.38, a PE ratio of -349.41 and a beta of 0.84.

In related news, VP Dong Chune Christopher Chung sold 12,642 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $42.91, for a total transaction of $542,468.22. Following the completion of the transaction, the vice president now directly owns 141,414 shares of the company’s stock, valued at $6,068,074.74. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director William M. Moore sold 5,000 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $41.01, for a total value of $205,050.00. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Natus Medical (BABY) Getting Somewhat Favorable Press Coverage, Report Finds” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Insider Buying and Selling by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with's FREE daily email newsletter.